The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Hims stock has rallied almost 22% this week on enthusiasm after the FDA said it will allow compounded versions of Lilly's ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Weight-loss jabs are “not the holy grail”, the NHS medical director has said ...

Eighty states, cities, counties, school boards and unions have joined litigation in a New Jersey district court against the three major pharmacy middlemen.

Weight-loss supplements are rebranding as “GLP-1 boosters.” They’re nothing like Ozempic. If you had come across the ...

Weight loss jabs are not a “holy grail” and will not solve the obesity crisis on their own, England’s top doctor has said.

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of the wildly popular drug.

I don’t think suddenly we’ve got X amount of unemployed people and we all give them Mounjaro and once they start losing ...

Adam Green, chief executive of unemployment charity Yes Manchester, said obesity was low on the list of reasons why some ...